Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Small Cell 1

Interventions

pembrolizumab 81Carboplatin 76Cisplatin 60Paclitaxel 59Specimen Handling 56Magnetic Resonance Spectroscopy 56Gemcitabine 48Docetaxel 38Dexamethasone 37Oxaliplatin 34Fluorouracil 34Bevacizumab 34Pemetrexed 33Leucovorin 33Doxorubicin 33Cyclophosphamide 32durvalumab 29Radiotherapy 29Radiation 29Capecitabine 29Rituximab 26Letrozole 25Irinotecan 24Etoposide 24Vincristine 23Nivolumab 23Lenalidomide 22Taxes 21Prednisone 21Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × EC regimen × 30 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡